Invivyd Inc.
$ 1.70
-0.58%
26 Feb - close price
- Market Cap 482,198,000 USD
- Current Price $ 1.70
- High / Low $ 1.76 / 1.68
- Stock P/E N/A
- Book Value 0.43
- EPS -0.45
- Next Earning Report 2026-03-19
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.68 %
- 52 Week High 3.07
- 52 Week Low 0.46
About
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases in the United States. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$10.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-15 | 2025-05-07 | 2025-03-26 | 2024-11-07 | 2024-08-14 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -0.06 | -0.12 | -0.14 | -0.15 | -0.51 | -0.4 | -0.38 | -0.67 | -0.36 | -0.46 | -0.32 | -0.25 |
| Estimated EPS | -0.07 | -0.02 | -0.01 | -0.1 | -0.35 | -0.37 | -0.47 | -0.42 | -0.5 | -0.34 | -0.3 | -0.39 |
| Surprise | 0.01 | -0.1 | -0.13 | -0.05 | -0.16 | -0.03 | 0.09 | -0.25 | 0.14 | -0.12 | -0.02 | 0.14 |
| Surprise Percentage | 14.2857% | -500% | -1300% | -50% | -45.7143% | -8.1081% | 19.1489% | -59.5238% | 28% | -35.2941% | -6.6667% | 35.8974% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-19 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.06 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IVVD
2026-02-24 11:53:20
Invivyd (Nasdaq: IVVD) has published a peer-reviewed model demonstrating that serum monoclonal antibody levels can predict clinical protection against symptomatic COVID-19, regardless of Omicron-era variants. This model, based on CANOPY Phase 3 data for pemivibart, suggests meaningful protection even at low antibody concentrations and could streamline regulatory pathways by allowing assessment of clinical efficacy from laboratory measurements. The company believes this variant-agnostic approach will enhance the development and use of new monoclonal antibody options for patients.
2026-02-21 16:12:12
The FDA has granted Emergency Use Authorization (EUA) to Invivyd's Pemgarda™ (pemivibart), a monoclonal antibody designed to prevent COVID-19 in immunocompromised adults and adolescents. This authorization marks a significant achievement for Invivyd, following its predecessor Adagio Therapeutics' failed lead candidate. Pemgarda is a re-engineered version of Adagio's ADG20, and Invivyd plans to target its commercial efforts toward a specific high-risk immunocompromised population in the U.S.
2026-02-21 00:02:00
A recent Lobbying Disclosure Act filing revealed that INVIVYD INC. (IVVD) disclosed $20,000 in lobbying expenditures for Q4 2025, with lobbying issues listed as "None." The article also details recent insider trading activity, including significant sales by multiple executives, and discusses hedge fund movements in IVVD stock. Additionally, it highlights recent "Buy" and "Overweight" analyst ratings with a median price target of $10.0 from four analysts.
2026-02-20 00:51:32
Invivyd's Chief Human Resources Officer, Julie Green, sold approximately $63,350 worth of company stock across two days in February 2026. These sales followed the exercise of options for 99,000 shares and were primarily to cover tax obligations from vested restricted stock units. Despite Green's stock sales and a year-to-date decline for Invivyd, the company's stock has shown strong performance over the past six months and is progressing with its Phase 3 LIBERTY trial for a monoclonal antibody candidate.
2026-02-19 20:53:14
Invivyd's CFO, William Duke, sold 19,663 shares of company stock for over $30,000, reducing his stake by 13.26%. This sale, along with other insider sales totaling over 220,000 shares, signals potentially negative insider sentiment. Shares were up 6.5% on lower-than-average volume, and analysts currently have a "Hold" consensus rating for Invivyd.
2026-02-19 18:14:02
Invivyd's Chief Scientific Officer, Robert D. Allen III, sold shares of the company's common stock totaling approximately $58,600 on February 17 and 18, 2026, to cover tax obligations. These transactions were executed under a pre-arranged trading plan, and Allen still directly owns 114,487 shares. In related news, Invivyd received positive feedback from the FDA for its Phase 3 LIBERTY trial and announced a partnership with Olympic gold medalist Lindsey Vonn for an education campaign.
